ATVO
Activeport Group Ltd
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
0
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Activeport Group Ltd - Option Expiring 27-Nov-2027 Deferred
π Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in ATVO
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in ATVO
N/A
ATVO investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in ATVO also invest in...
Want more shares? Try these...
Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The firm is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The firm's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The firm's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.
π Performance (5Yr p.a)
7.92%
π Share price
$0.10 AUD
𧬠BIOTECHNOLOGY
The Agency Group Australia Ltd. engages in providing real estate and financial services. The company is headquartered in Perth, Western Australia. The company went IPO on 2007-12-18. The Companyβs principal activity consists of real estate services and related activities. The company segments include Real Estate Property Services and Mortgage Origination Services. Its Real Estate and Property Services segment is engaged in the provision of real estate services including selling of property, settlement agent services, and property management. Its Mortgage Origination Services segment is engaged in the provision of mortgage broking services. The firm's wholly owned subsidiaries include Agency Partners WA Pty Ltd, Ausnet Financial Planning Services Pty Ltd, Ausnet Financial Pty Ltd, Ausnet Property Investment Fund Pty Ltd, Ausnet Real Estate Services Pty Ltd, Bushby & Co. Pty Ltd, Jelina Holdings Pty Ltd, Move Property Solutions Pty Ltd, The Agency Auctions NSW Pty Ltd, The Agency Canberra Pty Ltd, The Agency Commercial Real Estate Pty Ltd, and The Agency Marketing Pty Ltd.
π Performance (5Yr p.a)
-13.33%
π Share price
$0.02 AUD
π REAL ESTATE
ActivePort Group Ltd. develops software. The company is headquartered in Perth, Western Australia. The company went IPO on 2021-10-20. Its segments include ActivePort Software, Managed Service Provider (MSP), Network and Corporate services. Its assets are its network orchestration software, its network-as-service platform, and its information systems managed services business. The ActivePort software business offers software to customers that use it to orchestrate their networks and connect their customers to the cloud. The network as a service (NaaS) platform called Global Edge enables organizations to connect their operations to the cloud using a self-service Web interface. The managed services business delivers mission-critical information technology, services and support to enterprise customers across Australia and parts of Southeast Asia. The company helps its customers provide on-demand services, network device configuration and connections to cloud providers.
π Share price
$0.02 AUD
π€ TECHNOLOGY